

chain nodes :

35 37 38 39 40 41 42 43 44 45 46

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21  
22 23 24 25 26 27 28 29 30

chain bonds :

35-37 35-38 38-39 38-40 40-41 41-42 42-43 42-44 44-45 45-46

ring bonds :

1-2 1-6 1-7 2-3 2-10 3-4 4-5 5-6 7-8 8-9 9-10 11-12 11-16 11-17  
12-13 12-20 13-14 14-15 15-16 17-18 18-19 19-20 21-22 21-26 21-27  
22-23 22-30 23-24 24-25 25-26 27-28 28-29 29-30

exact/norm bonds :

35-37 38-39 38-40 42-43 45-46

exact bonds :

1-7 2-10 7-8 8-9 9-10 11-17 12-20 17-18 18-19 19-20 21-27 22-30  
27-28 28-29 29-30 35-38 40-41 41-42 42-44 44-45

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16  
21-22 21-26 22-23 23-24 24-25 25-26

isolated ring systems :

containing 1 : 11 : 21 :


G1:[\*1],[\*2],[\*3]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom  
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom  
18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom  
26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 35:CLASS 37:CLASS 38:CLASS  
39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS  
46:Atom

=&gt;

Uploading C:\Program Files\Stnexp\Queries\10667286.str



chain nodes :

35 37 38 39 40 41 42 43 44 45 46

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23  
24 25 26 27 28 29 30

chain bonds :

35-37 35-38 38-39 38-40 40-41 41-42 42-43 42-44 44-45 45-46

ring bonds :

1-2 1-6 1-7 2-3 2-10 3-4 4-5 5-6 7-8 8-9 9-10 11-12 11-16 11-17 12-13  
12-20 13-14 14-15 15-16 17-18 18-19 19-20 21-22 21-26 21-27 22-23 22-30  
23-24 24-25 25-26 27-28 28-29 29-30

exact/norm bonds :

35-37 38-39 38-40 42-43 45-46

exact bonds :

1-7 2-10 7-8 8-9 9-10 11-17 12-20 17-18 18-19 19-20 21-27 22-30 27-28  
28-29 29-30 35-38 40-41 41-42 42-44 44-45

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16 21-22  
21-26 22-23 23-24 24-25 25-26

isolated ring systems :

containing 1 : 11 : 21 :

G1:[\*1],[\*2],[\*3]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom  
 29:Atom 30:Atom 35:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS  
 42:CLASS 43:CLASS 44:CLASS 45:CLASS 46:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 17:29:57 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 390 TO ITERATE

100.0% PROCESSED 390 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 6616 TO 8984

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> => s l1 sss ful

FULL SEARCH INITIATED 17:31:03 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 7819 TO ITERATE

100.0% PROCESSED 7819 ITERATIONS

10 ANSWERS

SEARCH TIME: 00.00.01

L3 10 SEA SSS FUL L1

=> => s l3

L4 4 L3

=> d l4 1-4 bib,ab,hitstr

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:832787 CAPLUS

DN 137:337786

TI Preparation of chiral alkylaminochroman derivatives as  $\beta$ 3-adrenoreceptor agonists

IN O'Connor, Stephen J.; Ladouceur, Gaetan H.; Bullock, William H.; Campbell, Ann-Marie; Dai, Miao; Dally, Robert; Dumas, Jacques; Hatoum-Mokdad, Holia N.; Khire, Uday; Lee, Wendy; Liu, Qingjie; Lowe, Derek B.; Magnuson, Steven R.; Qi, Ning; Shelekhin, Tatiana E.; Shen, Quanrong; Smith, Roger A.; Wang, Ming

PA Bayer Corporation, USA

SO PCT Int. Appl., 193 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085891	A1	20021031	WO 2002-US12940	20020422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003078260	A1	20030424	US 2002-131448	20020422
US 6660752	B2	20031209		
EP 1389202	A1	20040218	EP 2002-723958	20020422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004072828	A1	20040415	US 2003-666903	20030917
PRAI US 2001-285719P	P	20010423		
US 2001-324518P	P	20010926		
US 2002-131448	A1	20020422		
WO 2002-US12940	W	20020422		

OS MARPAT 137:337786

AB This invention relates to novel 2,6-substituted chroman derivs. which are useful in the treatment of  $\beta$ 3-adrenoreceptor mediated conditions.

Title compds. I [wherein R = independently OH, :O, halo, CN, NO<sub>2</sub>, (halo)alkyl, CF<sub>3</sub>, NR<sub>1</sub>R<sub>1</sub>, SR<sub>1</sub>, OR<sub>1</sub>, SO<sub>2</sub>R<sub>2</sub>, OCOR<sub>2</sub>, NR<sub>1</sub>COR<sub>2</sub>, COR<sub>2</sub>, NR<sub>1</sub>SO<sub>2</sub>R<sub>2</sub>, or (un)substituted Ph or heterocyclyl; R<sub>1</sub> = independently H, (CH<sub>2</sub>)mO(CH<sub>2</sub>)mR<sub>5</sub>, or (un)substituted (cyclo)alkyl, Ph, or naphthyl; or NR<sub>1</sub>R<sub>1</sub> = heterocyclyl; R<sub>2</sub> = independently R<sub>1</sub>, OR<sub>1</sub>, NR<sub>1</sub>R<sub>1</sub>, or (un)substituted NHSO<sub>0</sub>-2-Ph, NHSO<sub>0</sub>-2-naphthyl, NHSO<sub>0</sub>-2-alkyl, or heterocyclyl; R<sub>3</sub> = H, alkyl, or COR<sub>3</sub>; R<sub>4</sub> = H, alkyl(phenyl), or alkylpyridyl; R<sub>5</sub> = H or CO<sub>2</sub>H; R<sub>6</sub> = H or (un)substituted alkyl or alkyl-SO<sub>0</sub>-2-alkyl; Ar = Ph or (fused) hetero(aryl); Y = halo, NO<sub>2</sub>, R<sub>6</sub>, SR<sub>1</sub>, SO<sub>0</sub>-2C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>R<sub>1</sub>, (CONR<sub>4</sub>CR<sub>4</sub>R<sub>4</sub>)pCO<sub>2</sub>R<sub>1</sub>, or (un)substituted Ph or heterocyclyl; m = 1-3; n = 0-5; p = 1 or 2; and pharmaceutically acceptable salts and esters thereof] were prepared as  $\beta$ 3-adrenoceptor agonists. For example, coupling of (2R)-6-iodo-3,4-dihydro-2H-chromene-2-carboxylic acid and (1R)-2-amino-1-(3-pyridinyl)ethanol•2HCl with 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide•HCl, and TEA in CH<sub>2</sub>Cl<sub>2</sub> gave the amide (74%). Reduction using borane-dimethylsulfide complex in THF afforded the


chromanmethaneamine II (84%). Over one hundred compds. of the invention demonstrated  $\beta_3$ -adrenergic receptor agonist activity with EC50 values  $\leq 1\mu\text{M}$ . I are useful in the treatment of  $\beta_3$ -adrenergic receptor mediated conditions, including obesity, diabetes, gastrointestinal disorders, cardiovascular disorders, and urinary disorders (no data).

IT **474111-20-1P**, (2R)-N-[(2R)-2-Hydroxy-2-(3-pyridinyl)ethyl]-6-iodo-3,4-dihydro-2H-chromene-2-carboxamide **474111-21-2P**, (2S)-N-[(2R)-2-Hydroxy-2-(3-pyridinyl)ethyl]-6-iodo-3,4-dihydro-2H-chromene-2-carboxamide **474112-71-5P**, (2R)-N-[(2R)-2-Hydroxy-2-(3-pyridinyl)ethyl]-6-nitro-3,4-dihydro-2H-chromene-2-carboxamide **474114-45-9P**, (2R)-N-[(2R)-2-[6-(2,5-Dimethyl-1H-pyrrol-1-yl)-3-pyridinyl]-2-hydroxyethyl]-6-iodo-3,4-dihydro-2H-chromene-2-carboxamide  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 ( $\beta_3$ -adrenoreceptor agonist; preparation of chiral alkylaminochroman derivs. as  $\beta_3$ -adrenoreceptor agonists)

RN 474111-20-1 CAPLUS

CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-N-[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]-6-iodo-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474111-21-2 CAPLUS

CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-N-[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]-6-iodo-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474112-71-5 CAPLUS

CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-N-[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]-6-nitro-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474114-45-9 CAPLUS

CN 2H-1-Benzopyran-2-carboxamide, N-[(2R)-2-[6-(2,5-dimethyl-1H-pyrrol-1-yl)-3-pyridinyl]-2-hydroxyethyl]-3,4-dihydro-6-iodo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE: CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:465994 CAPLUS

DN 137:33326

TI Preparation of chiral alkylaminochroman derivatives as  $\beta$ 3  
adrenoreceptor agonistsIN Ladouceur, Gaetan H.; Bullock, William H.; Magnuson, Steven R.; O'Connor,  
Stephen J.; Smith, Roger A.; Shen, Quanrong; Liu, Qingjie; Su, Ning;  
Velthuisen, Emil J.; Campbell, Ann-Marie; Ehrlich, Paul P.

PA Bayer Corporation, USA

SO PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002048134	A2	20020620	WO 2001-US46623	20011207
	WO 2002048134	A3	20030206		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002028816	A5	20020624	AU 2002-28816	20011207
	US 2003078258	A1	20030424	US 2001-8928	20011207
	US 6699860	B2	20040302		
	EP 1343778	A2	20030917	EP 2001-989934	20011207
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004524286	T2	20040812	JP 2002-549665	20011207
PRAI	US 2000-254735P	P	20001211		
	WO 2001-US46623	W	20011207		

OS MARPAT 137:33326

AB Title compds. [I; Ar = C<sub>6</sub>H<sub>5</sub>, heterocycle, benzoheterocycle; Y = halo, OR<sub>1</sub>, COOR<sub>1</sub>, CH<sub>2</sub>CH<sub>2</sub>COOH, 4-C<sub>6</sub>H<sub>4</sub>COOH, 4-C<sub>6</sub>H<sub>4</sub>COOCH<sub>3</sub>, 3-C<sub>6</sub>H<sub>4</sub>COOH, 2-naphthyl-6-carboxylic acid, etc.; m = 0, 1, 2, 3, 4, 5; n = 1, 2, 3; X = O, S, S:O, SO<sub>2</sub>; R = OH, halo, CN, NO<sub>2</sub>, CF<sub>3</sub>; R<sub>1</sub> = H, (CH<sub>2</sub>)<sub>n</sub>O(CH<sub>2</sub>)<sub>n</sub>COOH, (CH<sub>2</sub>)<sub>n</sub>O(CH<sub>2</sub>)<sub>n</sub>H; R<sub>2</sub> = R<sub>1</sub>, OR<sub>1</sub>, NR<sub>1</sub>R<sub>1</sub>, alkoxy, halo, NO<sub>2</sub>; R<sub>3</sub> = H, alkyl, C<sub>6</sub>H<sub>5</sub>CH<sub>2</sub>, COR<sub>2</sub>] are prepared as  $\beta$ 3 adrenergic receptor agonists. Title compds. I are useful in a pharmaceutical composition for the treatment of diabetes, impaired fasting glucose, impaired glucose tolerance, obesity, hypertriglyceridemia, hypercholesterolemia, hypercholesterolemia, lowering high-d. lipoprotein levels, atherosclerosis, cardiovascular diseases and related diseases, gastrointestinal disorders, neuro genetic inflammation, ocular hypertension, glaucoma, urol. disorders, benign prostatic hyperplasia, and, incontinence. Thus, the title compound II was prepared from (2R)-t-iodo-3,4-dihydro-2H-chroman-2-carboxylic acid, Me 4-iodobenzoate, and (2S)-1-amino-3-phenoxy-2-propanol via reduction and condensation. The title compound II was tested for  $\beta$ 3 agonistic activity with EC<sub>50</sub>  $\leq$  1 $\mu$ M.

IT 437764-11-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of chiral aminoalkylchroman derivs. as  $\beta$ 3 adrenoreceptor

agonists)

RN 437764-11-9 CAPLUS

CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-N-[(2S)-2-hydroxy-3-phenoxypropyl]-6-iodo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1999:421677 CAPLUS  
 DN 131:73558  
 TI Preparation of chromansulfonamides as  $\beta$ -3 adrenoreceptor agonists  
 IN Ladouceur, Gaetan H.; Connell, Richard D.; Baryza, Jeremy; Campbell, Ann-Marie; Lease, Timothy G.; Cook, James H.  
 PA Bayer Corporation, USA  
 SO PCT Int. Appl., 95 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

*Appl. PCT*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932475	A1	19990701	WO 1998-US24627	19981117
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9810489	A	19990520	ZA 1998-10489	19981117
	CA 2314925	AA	19990701	CA 1998-2314925	19981117
	AU 9914183	A1	19990712	AU 1999-14183	19981117
	AU 751015	B2	20020808		
	EP 1054881	A1	20001129	EP 1998-958070	19981117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001526281	T2	20011218	JP 2000-525412	19981117
	TW 502032	B	20020911	TW 1998-87118968	19981117
	US 6051586	A	20000418	US 1998-199014	19981123
	US 2003073839	A1	20030417	US 2000-520201	20000307
	US 2004072843	A1	20040415	US 2003-667286	20030919 ← Appl.
PRAI	US 1997-994585	A	19971219		
	US 1997-122061P	P	19971219		
	WO 1998-US24627	W	19981117		
	US 1998-199014	A3	19981123		
	US 2000-520201	B1	20000307		

OS MARPAT 131:73558

AB Title compds. [I; R = H, OH, O, halo, haloalkyl, alkyl, cyano, NO<sub>2</sub>, N(R<sub>1</sub>)<sub>2</sub>, SR<sub>1</sub>, OR<sub>1</sub>, SO<sub>2</sub>R<sub>2</sub>, CO<sub>2</sub>R<sub>2</sub>, COR<sub>2</sub>, NR<sub>1</sub>SO<sub>2</sub>R<sub>2</sub>, NR<sub>1</sub>COR<sub>2</sub>; R<sub>1</sub> = H, (substituted) alkyl, cycloalkyl, Ph, naphthyl; R<sub>2</sub> = R<sub>1</sub>, N(R<sub>1</sub>)<sub>2</sub>; R<sub>3</sub> = H, alkyl, RAr<sub>1</sub>CH(OH)CH<sub>2</sub>; Ar<sub>1</sub> = Ar<sub>1</sub>OCH<sub>2</sub>, Ph, (fused) heterocyclyl; m = 1-3; n = 0-4; X = piperazinylsulfonyl, NR<sub>3</sub>SO<sub>2</sub>; Ar<sub>2</sub> = (substituted) (fused) Ph, heterocyclyl; Y = OY, NR<sub>1</sub>, NR<sub>1</sub>CO, (oxo-substituted) cycloalkyl, heterocyclyl; p = 0, 1; R<sub>4</sub> = H, R<sub>1</sub>, R<sub>2</sub>, oxo, (substituted) heteroalkyl, alkyl, haloalkyl], were prepared for treatment of diabetes and obesity (no data). Thus, (R)-(pyrid-3-yl)oxirane (preparation given) and 2-aminomethylchroman-6-sulfonic acid [4-[4-(3-cyclopentylpropyl)-5-oxo-4,5-dihydrotetrazol-1-yl]phenyl]amide (preparation given) were refluxed in EtOH/H<sub>2</sub>O to give 11% title compound (II).

IT 228710-21-2P 228710-31-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of chromansulfonamides as  $\beta$ -3 adrenoreceptor agonists)

RN 228710-21-2 CAPLUS


CN 2H-1-Benzopyran-2-carboxamide, 6-[[[4-[4-(3-cyclopentylpropyl)-4,5-dihydro-5-oxo-1H-tetrazol-1-yl]phenyl]amino]sulfonyl]-N-[(2R)-2-[6-(2,5-dimethyl-1H-pyrrol-1-yl)-3-pyridinyl]-2-hydroxyethyl]-3,4-dihydro-, (2S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 228710-31-4 CAPLUS


CN 2H-1-Benzopyran-2-carboxamide, 6-[[[4-[4-(3-cyclopentylpropyl)-4,5-dihydro-5-oxo-1H-tetrazol-1-yl]phenyl]amino]sulfonyl]-3,4-dihydro-N-[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 6      THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1996:646308 CAPLUS  
 DN 125:300822  
 TI Preparation of N-chromanyl and N-chromanylmethyl 2-amino-1-phenylethanol compounds as adrenergic  $\beta_3$ -receptor stimulants  
 IN Tsucha, Susumu; Fukuzaki, Atsushi; Takenawa, Noriko; Ozaka, Kazuya  
 PA Tokyo Tanabe Co, Japan  
 SO Jpn. Kokai Tokkyo Koho, 10 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08198866	A2	19960806	JP 1995-6912	19950120
PRAI	JP 1995-6912		19950120		
OS	MARPAT 125:300822				

AB The title compds. (I; X = H, halo; n = 0-1; Y = H, OH, lower alkoxy, carboxymethoxy, lower alkoxycarbonylmethoxy) and their pharmacol. acceptable salts are prepared I show intestinal motility inhibition and antidiarrhea activity and are useful for the treatment of gastrointestinal diseases accompanied by unusual tension of smooth muscle. Thus, 6-methoxychroman-3-carboxylic acid (2R)-[2-(3-chlorophenyl)-2-hydroxyethyl]amide (preparation given) was reduced by BH<sub>3</sub>.Et<sub>2</sub>S in THF to give (1R) I (X = 3-Cl, n = 0, Y = 6'-OMe), which inhibited 60% diarrhea at 1 mg/kg p.o. in rats.

IT **182570-13-4P**, 6-Methoxychroman-3-carboxylic acid [2-(3-chlorophenyl)-2-hydroxyethyl]amide  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of 2-amino-1-phenylethanol compds. as adrenergic  $\beta_3$ -receptor stimulators for treatment of gastrointestinal diseases)

RN 182570-13-4 CAPLUS

CN 2H-1-Benzopyran-3-carboxamide, N-[2-(3-chlorophenyl)-2-hydroxyethyl]-3,4-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




IT **182570-24-7P**, (3R)-6-Methoxychroman-3-carboxylic acid 2R-[2-(3-chlorophenyl)-2-hydroxyethyl]amide **182821-95-0P**, (3S)-6-Methoxychroman-3-carboxylic acid (2R)-[2-(3-chlorophenyl)-2-hydroxyethyl]amide  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of 2-amino-1-phenylethanol compds. as adrenergic  $\beta_3$ -receptor stimulators for treatment of gastrointestinal diseases)

RN 182570-24-7 CAPLUS

CN 2H-1-Benzopyran-3-carboxamide, N-[2-(3-chlorophenyl)-2-hydroxyethyl]-3,4-dihydro-6-methoxy-, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 182821-95-0 CAPLUS

CN 2H-1-Benzopyran-3-carboxamide, N-[2-(3-chlorophenyl)-2-hydroxyethyl]-3,4-dihydro-6-methoxy-, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=&gt; =&gt; d his

(FILE 'HOME' ENTERED AT 17:29:15 ON 31 AUG 2004)

FILE 'STNGUIDE' ENTERED AT 17:29:19 ON 31 AUG 2004

FILE 'HOME' ENTERED AT 17:29:24 ON 31 AUG 2004

FILE 'REGISTRY' ENTERED AT 17:29:29 ON 31 AUG 2004

L1               STRUCTURE UPLOADED  
 L2               2 S L1 SSS SAM  
 L3               10 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 17:31:10 ON 31 AUG 2004

L4               4 S L3

FILE 'CAOLD' ENTERED AT 17:31:34 ON 31 AUG 2004

=&gt; s 13

L5               0 L3

=&gt; log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

176.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-2.80

STN INTERNATIONAL LOGOFF AT 17:31:44 ON 31 AUG 2004